The Ohio State University, Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
Ann N Y Acad Sci. 2009 Dec;1182:39-46. doi: 10.1111/j.1749-6632.2009.05071.x.
Interleukin 21 (IL-21) is produced by activated CD4(+) T cells. The IL-21R shares the common receptor gamma-chain with IL-2, IL-4, IL-7, IL-9, and IL-15, is widely expressed on immune cells, and mediates a variety of effects on the immune system. IL-21 enhances the proliferation, antigen-induced activation, clonal expansion, IFN-gamma production, and cytotoxicity of NK cells and T cells. The antitumor actions of IL-21 have been variously attributed to NK cell and CD8(+) T cell cytotoxicity, CD4(+) T cell help, NKT cells, and the antiangiogenic properties induced by IFN-gamma secretion. In clinical trials IL-21 has been well tolerated and induces a unique pattern of immune activation. IL-21 is therefore an excellent candidate for use in immune therapy.
白细胞介素 21(IL-21)由活化的 CD4(+) T 细胞产生。IL-21R 与 IL-2、IL-4、IL-7、IL-9 和 IL-15 共享共同的受体γ链,广泛表达于免疫细胞上,并介导对免疫系统的多种影响。IL-21 增强 NK 细胞和 T 细胞的增殖、抗原诱导的激活、克隆扩增、IFN-γ 产生和细胞毒性。IL-21 的抗肿瘤作用归因于 NK 细胞和 CD8(+) T 细胞的细胞毒性、CD4(+) T 细胞的辅助作用、NKT 细胞以及 IFN-γ 分泌诱导的抗血管生成特性。在临床试验中,IL-21 具有良好的耐受性,并诱导出独特的免疫激活模式。因此,IL-21 是免疫治疗的理想候选药物。